Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Myasthenia Gravis 1

Interventions

rozanolixizumab 11efgartigimod alfa 10zilucoplan 8Prednisone 8Cyclophosphamide 8ravulizumab 7Rituximab 7Pyridostigmine Bromide 7telitacicept 6fludarabine 6Tacrolimus 6Mycophenolic Acid 6eculizumab 5Immunoglobulins, Intravenous 5Hizentra 4Azathioprine 4Steroids 3HBM9161 3Data Collection 3Amifampridine 3thymoglobulin 2inebilizumab 2Thymectomy 2Prednisolone 2Methylprednisolone 2Methotrexate 2Exercise 2Diagnostic Self Evaluation 2Blood Specimen Collection 2tofacitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myasthenia Gravis × apraclonidine × Clear all
NCT05045248 2021-09-16

Efficacy of Apraclonidine Eye Drops in the Treatment of Ptosis Secondary to Myasthenia Gravis

American University of Beirut Medical Center

Phase 2 Completed
10 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡